Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer patient samples
AMSTERDAM, May 22, 2025 (GLOBE NEWSWIRE) -- Avidicure, a biotechnology company pioneering an entirely new dual agonistic, multifunctional antibody modality with broad applicability in oncology, today announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2025, in Chicago, Illinois. The presentation will highlight preclinical data supporting Avidicure's lead oncology program, AVC-S-101, a TROP2-targeting booster for the treatment of non-small cell lung cancer and several other cancer indications.
Avidicure's first-in-class dual agonistic multifunctional AVC-Boosters are designed to harness the full power of the immune system, and are avidity engineered to specifically and safely target only cancer cells. AVC-S-101 has shown prolonged and significantly improved tumor control in mice models by activating expansion and enhanced cytotoxicity of immune cells. In human non-small cell lung cancer samples freshly isolated from surgically resected tumors, AVC-S-101 demonstrated strong activation of the patient's own adaptive and innate immune cells, underscoring its potential as a monotherapy for cancer.
'After announcing our $50M seed funding last month, this presentation at ASCO 2025 marks another important milestone for Avidicure,' said Arthur Lahr, Chief Executive Officer of Avidicure. 'The data presented further demonstrate the unique mechanism of action of our AVC-Booster platform and programs. We are on track with IND enabling development of our lead multifunctional antibody targeting TROP2 for the treatment of non-small cell lung cancer and several other cancer indications.'
Poster presentation details:
Title: Avidity engineered multifunctional antibodies for stimulation and orchestration of innate and adaptive immune cells in tumor tissues.Poster Board: 38Abstract number: 8558Session Type and Title: Poster Session – Lung Cancer/Non-Small Cell MetastaticSession Date and Time: May 31st, 2025, 1:30 – 4:30 PM CDTPresenters: Robert Friesen, PhD & Sophie Poznanski, PhD
Avidicure will also be attending the BIO International Convention being held June 16 – 19, 2025, in Boston, Massachusetts. The company has been invited to give a corporate presentation titled 'First-in-class dual agonistic multifunctional antibodies that modulate the full immune system' on June 17th at 1:30 PM ET in Room 153A.
About Avidicure
Avidicure is a biotechnology company pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality, 'AVC-Boosters,' designed to safely deliver targeted and potent immune-modulating monotherapy for cancer patients. The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers, and antibody-drug conjugates (ADCs). AVC-Boosters unlock strong and orchestrated immunological responses, harnessing the full power of the innate and adaptive immune system. Avidicure is based in the Netherlands and is supported by a syndicate of top-tier investors led by EQT Life Sciences. For more information, please visit www.avidicure.com or follow the company on LinkedIn.
Contact:
Investor RelationsChristina Tartagliachristina.tartaglia@precisionaq.com
Media RelationsColleen Ketchumcolleen.ketchum@precisionaq.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
32 minutes ago
- Fast Company
Fear of Trump's tariffs sparked a rush on used cars—now prices are easing
Used car prices ticked down slightly last month in spite of uncertainty around tariffs, but buying a new old whip still costs more than it used to. In April, the average cost for a used vehicle shot up as consumers raced to lock in purchases ahead of potential price hikes driven by Trump's ongoing trade wars. The Manheim Used Vehicle Value Index from Cox Automotive, which tracks used car sales in the U.S., showed a 1.4% drop in prices last month, but prices are still up 4% compared to the same time last year. In April, used car prices saw their biggest spike since October 2023. 'While the market continues to digest the impact of tariffs, we could see a bit higher levels of wholesale depreciation over the summer,' Cox Automotive Senior Director of Economic and Industry Insights Jeremy Robb said in the report, while noting that low inventory could act as a counterbalance, driving prices back up. Compared to a year ago, luxury cars saw the biggest price increase at 6.5%, with SUVs close behind with a 5.2% year-over-year increase. Electric vehicle prices were up 3.1% compared to the same time last May. Used car prices in the U.S. have been a telling indicator of market forces in recent years. In the pandemic's early days, supply chain issues constricted the availability of new cars, driving more buyers to the used market. That demand sent used car prices up, and they mostly stayed that way. In March, President Trump announced a 25% tariff on imported cars and car parts, sowing fresh inflation concerns and sending supply chains into chaos again. Trump later eased tariffs for vehicles assembled in the U.S. using foreign parts – a reprieve intended to give U.S. automakers a break while they scramble to determine the feasibility of building domestic supply chains to replace parts sourcing abroad.
Wall Street Journal
32 minutes ago
- Wall Street Journal
The Score: Tesla, Cleveland-Cliffs, Dollar General and More Stocks That Defined the Week
The Score is a weekly review of the biggest stock moves and the news that drove them. U.S. steelmakers rallied on President Trump's recent move to double steel and aluminum tariffs to 50%.
TechCrunch
34 minutes ago
- TechCrunch
Anthropic appoints a national security expert to its governing trust
A day after announcing new AI models designed for U.S. national security applications, Anthropic has appointed a national security expert, Richard Fontaine, to its long-term benefit trust. Anthropic's long-term benefit trust is a governance mechanism that Anthropic claims helps it promote safety over profit, and which has the power to elect some of the company's board of directors. The trust's other members include Centre for Effective Altruism CEO Zachary Robinson, Clinton Health Access Initiative CEO Neil Buddy Shah, and Evidence Action President Kanika Bahl. In a statement, Anthropic CEO Dario Amodei said that Fontaine's hiring will '[strengthen] the trust's ability to guide Anthropic through complex decisions' about AI as it relates to security. 'Richard's expertise comes at a critical time as advanced AI capabilities increasingly intersect with national security considerations,' Amodei continued. 'I've long believed that ensuring democratic nations maintain leadership in responsible AI development is essential for both global security and the common good.' Fontaine, who as a trustee won't have a financial stake in Anthropic, previously served as a foreign policy adviser to the late Sen. John McCain and was an adjunct professor at Georgetown teaching security studies. For more than six years, he led the Center for A New American Security, a national security think tank based in Washington, D.C., as its president. Anthropic has increasingly engaged U.S. national security customers as it looks for new sources of revenue. In November, the company teamed up with Palantir and AWS, the cloud computing division of Anthropic's major partner and investor, Amazon, to sell Anthropic's AI to defense customers. To be clear, Anthropic isn't the only top AI lab going after defense contracts. OpenAI is seeking to establish a closer relationship with the U.S. Defense Department, and Meta recently revealed that it's making its Llama models available to defense partners. Meanwhile, Google is refining a version of its Gemini AI capable of working within classified environments, and Cohere, which primarily builds AI products for businesses, is also collaborating with Palantir to deploy its AI models. Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW Fontaine's hiring comes as Anthropic beefs up its executive ranks. In May, the company named Netflix co-founder Reed Hastings to its board.
